A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

BACKGROUND: Cabozantinib is an oral MET/VEGFR2 inhibitor. A recent phase II study of cabozantinib (100mg daily) demonstrated improved bone scans in subjects with metastatic castration-resistant prostate cancer (mCRPC), but adverse events (AEs) caused frequent dose reductions. This study was designed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Lee, Richard J., Saylor, Philip J., Michaelson, M. Dror, Rothenberg, S. Michael, Smas, Malgorzata E., Miyamoto, David T., Gurski, Carol A., Xie, Wanling, Maheswaran, Shyamala, Haber, Daniel A., Goldin, Jonathan G., Smith, Matthew R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3684567/
https://ncbi.nlm.nih.gov/pubmed/23553848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0319
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados